The Use of Vascular Endothelial Growth Factor Inhibitors in Patients with Proliferative Diabetic Retinopathy
https://doi.org/10.18008/1816-5095-2022-2-405-412
Abstract
Diabetic retinopathy (DR) have been taking a leading position among retinal disorders, causing a persistent and significant decrease in visual functions. The base of the disease is a retinal vascular microangiopathy, which induces a tissue ischemia and excessive production of vascular endothelial growth factors. The main method of treatment for this pathology is a laser photocoagulation. However, it is not always possible to perform appropriate laser photocoagulation, by that limiting its efficacy (cases of hard cataract and hemophthalmos). In addition, this type of treatment might have a number of serious complications, such as macular oedema, recurrent vitreous hemorrhages, the occurrence of fibrosis, atrophic changes in the retina, which leads to a decline in visual acuity and contrast sensitivity, worsening the visual field. Over the past 10 years, vascular endothelial growth factor inhibitors have been introduced into clinical practice, and showed their benefits in the treatment of disorders leading to a pathological angiogenesis. But due to the limited number of systematic observations, assessing the impact of these drugs, is necessary to investigate their efficacy and safety in patients with proliferative DR, in order to develop indications for their use. The purpose of the review is evaluation of the effect of vascular endothelial growth factor inhibitors on active neovascularization in patients with proliferative diabetic retinopathy. There is a literature of international clinical guidelines, randomized clinical trials with a varying level of evidence, articles and publications by groups of authors in the article.
About the Authors
V. Yu. Evgrafov
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
MD, Professor, responsible for work with residents and postgraduates, Ophthalmology department of the school of continuing medical education,
Ostrovitianov str., 1, Moscow, 117997
G. R. Kudasheva
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
postgraduate,
Ostrovitianov str., 1, Moscow, 117997
References
1. Shadrichev F.E., Shklyarov E.B., Grigorieva N.N. The use of anti-VEGF therapy in the treatment of diabetic macular edema. Ophthalmology journal = Oftalmologiceskie vedomosti. 2011;4(1):83–92 (In Russ.).
2. Budzinskaya M.V., Petrachkov D.V., Savochkina O.A., Arzhukhanov D.D. Classification of diabetic retinopathy. The Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2019;135(5):272–277 (In Russ.). DOI: 10.17116/oftalma2019135052272
3. Diabetic retinopathy. Medscape ophthalmology; last update May 22, 2019. https://emedicine.medscape.com/article/1225122-overview#a1
4. Poveschenko A.F., Konenkov V.I. Mechanisms and factors of angiogenesis. Advances in Physical Sciences = PhysicsUspekhi. 2010;41(2):68–89 (In Russ.).
5. Konenkov V.I., Klimontov V.V., Chernykh V.V., Tyan N.V. Anti-VEGF drugs in the treatment of diabetic macular edema. Diabetes = Sakharnyy diabet. 2013;4:78– 84 (In Russ.).
6. Balashevich L.I., Brezhesky V.V., Izmailov A.S. Ocular manifestations of diabetes. Saint Peterburg: SPbMAPO Publ.; 2004. 453 p. (In Russ.).
7. Lipatov D.V., Chistyakov T.A. Medical, laser and surgical treatment of secondary neovascular glaucoma in patients with diabetes mellitus. Glaucoma = Glaukoma. 2013;2:62–69 (In Russ.).
8. The Diabetic Retinopathy Study Research Group. “Indications for photocoagulation treatment of diabetic retinopathy”. Diabetic Retinopathy Study Report. Int Ophthalmol Clin. 1987;27:239–253. DOI: 10.1097/00004397-198702740-00004
9. The Diabetic Retinopathy Study Research Group. Indications for photocoagulation treatment of diabetic retinopathy. Diabetic Retinopathy Study Report. 14. Int Ophthalmol Clin 1987; 27:239–253. DOI: 10.1097/00004397-19870274000004
10. Rosenstein RB. Long-term stability and visual outcome after favourable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. Ophthalmology 1991;98:1575–1579. DOI: 10.1016/s0161-6420(91)32085-2
11. Basic and Clinical Science Course, 12th Edition. Retina and vitreous. American Academy of Ophthalmology publishing house, San Francisco, 2016–2017;96–97.
12. International Council of Ophthalmology Guidelines for Diabetic Eye Care. 2017:9– 10. http://www.icoph.org/enhancing_eyecare/diabetic_eyecare.html
13. Gentile R.C., Stegman Z., Liebmann J.M., Dayan A.R., Tello C.,Walsh J.B. Risk factors for ciliochoroidal effusion after panretinal photocoagulation. Ophthalmology. 1996;103:827–832. DOI: 10.1016/s0161-6420(96)30608-8
14. McDonald H.R., Schatz H. Macular edema following panretinal photocoagulation. Retina. 1985;5:5–10. DOI: 10.1097/00006982-198500510-00002
15. Jardeleza M.S., Miller J.W. Review of anti-VEGF therapy in proliferative diabetic retinopathy. Semin Ophthalmol. 2009;24:87–92. DOI: 10.1080/08820530902800330
16. Lipatov D.V., Lyshkanets O.I. Intravitreal therapy of diabetic macular edema in the Russian Federation: current state of the problem. The Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2019;135(4):128–140 (In Russ.).
17. Neroev V.V., Sarygina O.I., Levkina O.A. The role of vascular endothelial growth factor in the pathogenesis of diabetic retinopathy. The Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2009;2:58–60 (In Russ.).
18. Karpilova M.A., Durzhinskaya M.Kh. Anti-VEGF drugs in the treatment of neovascular glaucoma. The Russian Annals of Ophthalmology = Vestnik oftal’mologii. 2019;135(5):299–304 (In Russ.). DOI: 10.17116/oftalma2019135052299
19. Spaide R.F., Fisher Y.L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26:275– 278. DOI: 10.1097/00006982-200603000-00004
20. Avery R.L. Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment. Retina. 2006;26:352–354. DOI: 10.1016/j.ophtha.2006.05.064
21. Thew M. Rapid resolution of severe retinal neovascularisation in proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab (Avastin). Clin Exp Optometry. 2009;92:34–37. DOI: 10.1111/j.1444-0938.2008.00295.x
22. Sun J.K. The Diabetic Retinopathy Study Research Group. Rationale and Clinical Application of the DRCR.net Anti-VEGF Treatment Algorithm for Proliferative Diabetic Retinopathy. Ophthalmology. 2019:126(1):87-95. DOI: 10.1016/j.ophtha.2018.08.001
23. D’Amore P.A. Vascular endothelial cell growth factor-A: not just for endothelial cells anymore. Am J Pathol. 2007;171:14–18. DOI: 10.2353/ajpath.2007.070385
24. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA) Ophthalmologica. 2017;237:196–208.
25. Matsuyama K., Ogata N., Matsuoka M., Wada M., Takahashi K., Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol. 2010;94:1215–1218. DOI: 10.1136/bjo.2008.156810
26. Zehetner C., Kirchmair R., Huber S., Kralinger M.T., Kieselbach G.F. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with agerelated macular degeneration, and in patients with diabetic macular oedema. Br J Ophthalmol. 2013;97:454–459. DOI: 10.1136/bjophthalmol-2012-302451
27. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–1487. DOI: 10.1056/NEJM199412013312203
28. Chen G., Li W., Tzekov R., Jiang F., Mao S., Tong Y. Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema: a metaanalysis of randomized controlled trials. PLoS One 2014;9:e115797. DOI: 10.1371/ journal.pone.0115797
29. Brown D.M., Nguyen Q.D., Marcus D.M., Boyer D.S., Patel S., Feiner L., Schlottmann P.G., Rundle A.C., Zhang J., Rubio R.G., Adamis A.P., Ehrlich J.S., Hopkins J.J. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120:2013–2022. DOI: 10.1016/j.ophtha.2013.02.034
30. Elman M.J., Aiello L.P., Beck R.W., Bressler N.M., Bressler S.B., Edwards A.R., Ferris F.L., Friedman S.M., Glassman A.R., Miller K.M., Scott I.U., Stockdale C.R., Sun J.K. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117:1064–1077.e1035. DOI: 10.1016/j.ophtha.2010.02.031
31. The diabetic retinopathy clinical research network, T. Beaulieu. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic retinopathy: PatientCentered Outcomes From a randomized Clinical Trial. Aug.2016. DOI: 10.1016/j.ajo.2016.08.008
32. FDA, Professional Drug Information for Eylea. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125387lbl.pdf
33. Electronic medicines compendium, United Kingdom. Eylea prescription information.https://www.medicines.org.uk/emc/product/2879/smpc
34. FDA Approves Eylea (aflibercept) Injection for Diabetic Retinopathy, PM Regeneron May 13, 2019 — retrieved May 14, 2019. https://investor.regeneron.com/news-releases/news-release-details/fda-approves-eylear-aflibercept-injectionprefilled-syringe/
35. McCannel C.A. Meta-analysis of endophthalmitis after intravitreal injection of antivascular endothelial growth factor agents. Retina. 2011;31:654–661. DOI: 10.1097/IAE.0b013e31820a67e4
36. Scott I.U., Flynn Jr. H.W. Reducing the risk of endophthalmitis following intravitreal injections. Retina. 2007;27:10–12. DOI: 10.1097/IAE.0b013e3180307271
37. Fintak D.R., Shah G.K., Kj. Blinder, Regillo C.D., Pollack J.,Heier J.S. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina. 2008;28:1395–1399. DOI: 10.1097/IAE.0b013e3181884fd2
38. Pilli S., Kotsolis A., Spaide R.F., Slakter J., Freund K.B., Sorenson J. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 2008;145(5):879–882. DOI: 10.1016/j.ajo.2007.12.036
39. Doshi R.R., Leng T., Fung A.E. Reducing oral flora contamination of intravitreal injections with face mask or silence. Retina. 2012;32(3):473–476. DOI: 10.1097/IAE.0B013E31822C2958
40. Wen J.C., McCannel C.A., Mochon A.B., Garner O.B. Bacterial dispersal associated with speech in the setting of intravitreous injections. Arch Ophthalmol. 2011;129(12):1551–1554. DOI: 10.1001/archophthalmol.2011.227
41. Yeh P.T., Yang C.M., Lin Y.C., Chen M.S., Yang C.H. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina. 2009;29:768– 774. DOI: 10.1097/IAE.0b013e3181a3b7ef
42. Jonas J.B., Schmidbauer M., Rensch F. Progression of tractional retinal detachment following intravitreal bevacizumab. Acta Ophthalmol. 2009;87:571–572. DOI: 10.1111/j.1755-3768.2008.01225.x
43. Arevalo J.F., Maia M., Flynn Jr. H.W., Saravia M., Avery R.L., Wu L., Eid Farah M. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92:213– 216. DOI: 10.1136/bjo.2007.127142
44. Jalil A., Fenerty C., Charles S. Intravitreal bevacizumab (Avastin) causing acute glaucoma: an unreported complication. Eye. 2007;21:1541. DOI: 10.1038/sj.eye.6703018
45. Ahmadieh H., Shoeibi N., Entezari M., Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology 2009; 116:1943–1948. DOI: 10.1016/j.ophtha.2009.07.001
46. Arevalo J.F., Sanchez J.G., Lasave A.F., Wu L., Maia M., Bonafonte S. Intravitreal bevacizumab (Avastin) for diabetic retinopathy: the 2010 GLADAOF lecture. J Ophthalmol 2011; 2011: 584238. DOI: 10.1155/2011/584238
47. Bakri S.J., Pulido J.S., McCannel C.A., Hodge D.O., Diehl N., Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye 2009; 23(1): 181–185. DOI: 10.1038/sj.eye.6702938
48. Gismondi M., Salati C., Salvetat M.L., Zeppieri M., Brusini P. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009; 18(9):658–661. DOI: 10.1097/IJG.0b013e31819c4893
49. Frenkel R.E., Mani L., Toler A.R., Frenkel M.P. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol 2007; 143: 1034–1035. DOI: 10.1016/j.ajo.2007.01.052
50. Wu L., Martı´nez-Castellanos M.A., Quiroz-Mercado H., Arevalo J.F., Berrocal M.H., Farah M.E.. Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of IVB (Avastin): results of the PanAmerican Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 2008;246:81–87. DOI: 10.1007/s00417-007-0660-z
51. Ladas I.D., Karagiannis D.A., Rouvas A.A., Kotsolis A.I., Liotsou A., Vergados I. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections. Retina. 2009;29(3):313–318. DOI: 10.1097/IAE.0b013e31819a5f98
52. Loukopoulos V., Meier C., Gerding H. Hemorrhagic complications after intravitreal injections of ranibizumab in patients under coumarin-type anticoagulation. Klin Monbl Augenheilkd. 2010;227(4):289–291. DOI: 10.1055/s-0029-1245225
53. Mason 3rd J.O., Frederick P.A., Neimkin M.G., White Jr. M.F., Feist R.M., Thomley M.L. Incidence of hemorrhagic complications after intravitreal bevacizumab (avastin) or ranibizumab (lucentis) injections on systemically anticoagulated patients. Retina. 2010;30(9):1386–1389. DOI: 10.1097/IAE.0b013e3181e09739
54. Lee S.J., Koh H.J. Enlargement of the foveal avascular zone in diabetic retinopathy after adjunctive intravitreal bevacizumab (Avastin) with pars plana vitrectomy. J Ocul Pharmacol Ther. 2009;25:173–174. DOI: 10.1089/jop.2008.0092
55. Michaelides M., Fraser-Bell S., Hamilton R., Kaines A., Egan C., Bunce C. Macular perfusion determined by fundus fluorescein angiography at the 4-month time point in a prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (Bolt Study): Report 1. Retina. 2010;30:781–786. DOI: 10.1097/IAE.0b013e3181d2f145
56. Nishijima K., Ng Y.S., Zhong L., Bradley J., Schubert W., Jo N. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171:53–67. DOI: 10.2353/ajpath.2007.061237
57. Saint-Geniez M., Maharaj A.S., Walshe T.E., Tucker B.A., Sekiyama E., Kurihara T. Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS One. 2008;3:e3554. DOI: 10.1371/journal.pone.0003554
58. Maharaj A.S., D’Amore P.A. Roles for VEGF in the adult. Microvasc Res. 2007;74:100–113. DOI: 10.1016/j.mvr.2007.03.004
59. Csaky K. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. Am J Ophthalmol. 2009;148:647–656: DOI:10.1016/j.ajo.2009.06.014
60. Schmucker C., Ehlken C., Agostini H.T., Antes G., Ruecker G., Lelgemann M. A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard. PLoS One. 2012;7(8):E42701. DOI: 10.1371/journal.pone.0042701
61. The Royal College of Ophthalmologists. Statement.Bevacizumab (Avastin) Use in Medical Ophthalmology 2011. https://www.rcophth.ac.uk/2014/12/use-of-avastinbevacizumab-in-age-related-macular-degeneration-2/
62. Yeh P.T., Yang C.M., Lin Y.C., Chen M.S., Yang C.H. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina. 2009;29:768– 774. DOI: 10.1097/IAE.0b013e3181a3b7ef
63. Ahmadieh H., Shoeibi N., Entezari M., Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology. 2009;116:1943–1948. DOI: 10.1016/j.ophtha.2009.07.001
64. Moradian S., Ahmadieh H., Malihi M., Soheilian M., Dehghan M.H., Azarmina M. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008;246:1699–1705. DOI: 10.1007/s00417008-0914-4
65. Costagliola C., Cipollone U., Rinaldi M., della Corte M., Semeraro F., Romano M.R. Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up. Br J Clin Pharmacol. 2008;66:667–673. DOI: 10.1111/j.1365-2125.2008.03278.x
66. Chalam K.V., Gupta S.K., Grover S., Brar V.S., Agarwal S. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma. Eur J Ophthalmol. 2008;18:255–262. DOI: 10.1177/112067210801800214
67. Lim T.H., Bae S.H., Cho Y.J., Lee J.H., Kim H.K., Sohn Y.H. Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma. Korean J Ophthalmol. 2009;23:188–192. DOI: 10.3341/kjo.2009.23.3.188
68. Eid T.M., Radwan A., el-Manawy W., el-Hawary I. Intravitreal bevacizumab and aqueous shunting surgery for neovascular glaucoma: safety and efficacy. Can J Ophthalmol. 2009;44:451–456. DOI: 10.3129/i09-108
69. Filho J.A., Messias A., Almeida F.P., Ribeiro J.A., Costa R.A., Scott I.U. Panretinal photocoagulation (PRP) versus PRP plus intravitreal ranibizumab for highrisk proliferative diabetic retinopathy. Acta Ophthalmol. 2011;89:567–572. DOI: 10.1111/j.1755-3768.2011.02184.x
70. Cho W.B., Oh S.B., Moon J.W., Kim H.C. Panretinal photocoagulation combined with intravitreal bevacizumab in high-risk proliferative diabetic retinopathy. Retina. 2009;29:516–522. DOI: 10.1097/IAE.0b013e31819a5fc2
71. Early Treatment Diabetic Retinopathy Study Research Group. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology. 1987;761-774.
Review
For citations:
Evgrafov V.Yu., Kudasheva G.R. The Use of Vascular Endothelial Growth Factor Inhibitors in Patients with Proliferative Diabetic Retinopathy. Ophthalmology in Russia. 2022;19(2):405-412. (In Russ.) https://doi.org/10.18008/1816-5095-2022-2-405-412
Views:
596
Email this article 